Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:DTIL), showcasing a mix of bullish and…
Precision BioSciences Announces Receipt Of FDA Fast Track Designation For ECUR-506, iECURE’s Program For The Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers INVO Bioscience (NASDAQ:INVO) shares increased by 93.4% to $1.47 during Wednesday’s pre-market session. The market value of…
iECURE Announces FDA Clearance Of IND Application For ECUR-506 To Initiate OTC-HOPE Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.S.; NOTE: iECURE Has Licensed The ARCUS Nuclease For ECUR-506 From Precision BioSci…
Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editing-based therapy, in newborn males with neonatal onset Ornithine Transcarbamylase (OTC)
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell
• Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Earnings Preview: Precision BioSciences
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here’s what investors…
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 92.1% to $0.98 during Tuesday’s pre-market session. The company’s market cap stands…
Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?
TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S.
Why Precision BioSciences Stock Is Up Today
Precision BioSciences, Inc. (NASDAQ: DTIL) shares are trading higher Tuesday after the company announced it has signed a licensing agreement wit
Precision BioSciences Strikes $17.5M Gene Editing Deal with TG Therapeutics, Eyeing $288M in Future Milestones
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene